Published in Front Psychiatry on September 05, 2014
Adverse Events and Genomics in Schizophrenia (AEGIS) | NCT01966588
Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care (2004) 9.16
Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry (2005) 5.57
Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol (2004) 3.43
Visceral fat is an independent predictor of all-cause mortality in men. Obesity (Silver Spring) (2006) 3.29
Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology (2008) 3.04
Integrative health coaching for patients with type 2 diabetes: a randomized clinical trial. Diabetes Educ (2010) 2.09
Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry (2006) 2.00
Early detection and intervention with schizophrenia: rationale. Schizophr Bull (1996) 1.86
Increased intrahepatic triglyceride is associated with peripheral insulin resistance: in vivo MR imaging and spectroscopy studies. Am J Physiol Endocrinol Metab (2007) 1.80
Visceral adiposity and its anatomical distribution as predictors of the metabolic syndrome and cardiometabolic risk factor levels. Am J Clin Nutr (2008) 1.80
Five-year follow-up of a randomized multicenter trial of intensive early intervention vs standard treatment for patients with a first episode of psychotic illness: the OPUS trial. Arch Gen Psychiatry (2008) 1.77
A multidimensional integrative medicine intervention to improve cardiovascular risk. J Gen Intern Med (2006) 1.73
Follow-up whole-body assessment of adipose tissue compartments during a lifestyle intervention in a large cohort at increased risk for type 2 diabetes. Radiology (2010) 1.71
Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol (2011) 1.63
Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry (2012) 1.59
Measurement site for waist circumference affects its accuracy as an index of visceral and abdominal subcutaneous fat in a Caucasian population. J Nutr (2010) 1.49
Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms. Pharmacol Ther (2009) 1.48
Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. Mol Psychiatry (2010) 1.39
First-episode schizophrenia: I. Early course parameters. Schizophr Bull (1996) 1.38
Writing SMART rehabilitation goals and achieving goal attainment scaling: a practical guide. Clin Rehabil (2009) 1.34
Early intervention for psychosis. Cochrane Database Syst Rev (2006) 1.32
Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opin Drug Metab Toxicol (2011) 1.31
Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry (2004) 1.21
Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. J Clin Psychiatry (2010) 1.13
Families' experience with seeking treatment for recent-onset psychosis. Psychiatr Serv (2009) 1.07
Symptom and functional outcomes for a 5 year early intervention program for psychoses. Schizophr Res (2011) 1.07
How successful are first episode programs? A review of the evidence for specialized assertive early intervention. Curr Opin Psychiatry (2014) 1.03
Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system. Pharmacol Ther (2012) 1.03
Schizophrenia: medical illness, mortality, and aging. Int J Psychiatry Med (2011) 1.01
Benefits of enriched intervention compared with standard care for patients with recent-onset psychosis: a metaanalytic approach. Can J Psychiatry (2007) 0.99
Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment. J Psychiatry Neurosci (2007) 0.99
Antipsychotic and psychostimulant drug combination therapy in attention deficit/hyperactivity and disruptive behavior disorders: a systematic review of efficacy and tolerability. Curr Psychiatry Rep (2013) 0.98
Visceral fat is a strong predictor of insulin resistance regardless of cardiorespiratory fitness in non-diabetic people. J Nutr Sci Vitaminol (Tokyo) (2010) 0.95
Independent effect of visceral adipose tissue on metabolic syndrome in obese adolescents. Horm Res (2008) 0.95
Self-reported motivation to smoke in schizophrenia is related to antipsychotic drug treatment. Schizophr Res (2008) 0.94
Management of physical health in patients with schizophrenia: practical recommendations. Eur Psychiatry (2010) 0.93
Cardiovascular aspects of antipsychotics. Curr Opin Psychiatry (2010) 0.92
Adiposity and eating behaviors in patients under second generation antipsychotics. Obesity (Silver Spring) (2008) 0.91
Case report of hemoglobin a1c and weight reduction in integrative health coaching. Glob Adv Health Med (2013) 0.89
The second-generation 'atypical' antipsychotics: similar improved efficacy but different neuroendocrine side effects. Psychoneuroendocrinology (2003) 0.89
Pharmacogenetics of antipsychotics: recent progress and methodological issues. Expert Opin Drug Metab Toxicol (2012) 0.88
Preclinical models of antipsychotic drug-induced metabolic side effects. Trends Pharmacol Sci (2010) 0.88
Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review. Eur Child Adolesc Psychiatry (2013) 0.88
Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats. J Psychiatry Neurosci (2012) 0.86
Prevalence and patterns of antipsychotic use in youth at the time of admission and discharge from an inpatient psychiatric facility. J Clin Psychopharmacol (2014) 0.86
Personalized health planning with integrative health coaching to reduce obesity risk among women gaining excess weight during pregnancy. Glob Adv Health Med (2013) 0.85
Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats. Neuropharmacology (2011) 0.85
Predictors of starting to smoke cigarettes in patients with first episode psychosis. Schizophr Res (2009) 0.84
Prediabetes in patients treated with antipsychotic drugs. J Clin Psychiatry (2011) 0.84
Behavioral health coaching for rural-living older adults with diabetes and depression: an open pilot of the HOPE Study. BMC Geriatr (2012) 0.84
Prevalence of the metabolic syndrome in veterans with schizophrenia. J Psychiatr Pract (2006) 0.83
A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model. Prog Neuropsychopharmacol Biol Psychiatry (2010) 0.83
Effects of chronic exercise and treatment with the antipsychotic drug olanzapine on hippocampal volume in adult female rats. Neuroscience (2013) 0.81
Metabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine. PLoS One (2013) 0.81
Routine exercise ameliorates the metabolic side-effects of treatment with the atypical antipsychotic drug olanzapine in rats. Int J Neuropsychopharmacol (2013) 0.80
Antipsychotic polypharmacy increases metabolic dysregulation in female rats. Exp Clin Psychopharmacol (2013) 0.80
Switching to aripiprazole as a strategy for weight reduction: a meta-analysis in patients suffering from schizophrenia. J Obes (2010) 0.80
Conceptual and methodological issues in the design of clinical trials of antipsychotics for the treatment of schizophrenia. CNS Drugs (2007) 0.80
Therapeutic effects of maximal strength training on walking efficiency in patients with schizophrenia - a pilot study. BMC Res Notes (2012) 0.79
Management of Medication-Related Cardiometabolic Risk in Patients with Severe Mental Illness. Curr Cardiovasc Risk Rep (2013) 0.78
Primary care providers' views on metabolic monitoring of outpatients taking antipsychotic medication. Psychiatr Serv (2013) 0.78
Antidiabetic-drug combination treatment for glucose intolerance in adult female rats treated acutely with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry (2013) 0.78
Cardiovascular effects of acute treatment with the antipsychotic drug olanzapine in rats. Vascul Pharmacol (2014) 0.78
Pharmacological treatment of antipsychotic-induced dyslipidemia and hypertension. Int Clin Psychopharmacol (2014) 0.77
Clozapine and cardiometabolic health in chronic schizophrenia: correlations and consequences in a clinical context. Australas Psychiatry (2010) 0.76
Early intervention and sustaining the management of vulnerability. Aust N Z J Psychiatry (2000) 0.76
The prodrome and clinical risk for psychotic disorders. Child Adolesc Psychiatr Clin N Am (2013) 0.76